BABA vs PASW
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.
PASW presents a classic 'value trap' scenario, characterized by a stable Piotroski F-Score of 5/9 but catastrophic operational decay. While the balance sheet remains relatively clean with low debt and a healthy current ratio, the company has suffered a massive 62% year-over-year revenue collapse and negative profit margins. The 95% decline in share price over the last year reflects a fundamental breakdown in the business model, which is not offset by the low Price-to-Book ratio of 0.51.
Compare Another Pair
Related Comparisons
BABA vs PASW: Head-to-Head Comparison
This page compares Alibaba Group Holding Limited (BABA) and Ping An Biomedical Co., Ltd. (PASW) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.